To The Moon

CERo Therapeutics Holdings said Friday that the US Food and Drug Administration has cleared its investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.The company said it expects to start the phase 1 trial in Q1 of 2025.CERo's shares soared past 79% in recent trading.Price: 0.34, Change: +0.15, Percent Change: +79.22

CERo Therapeutics Holdings said Friday that the US Food and Drug Administration has cleared its investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.The company said it expects to start the phase 1 trial in Q1 of 2025.CERo's shares soared past 79% in recent trading.Price: 0.34, Change: +0.15, Percent Change: +79.22

$Faraday Future$ jumped 5% in premarket after shooting up 124% on Thursday as it reversed about a week's worth of decline.The company did release any news on Thursday or post any new SEC filings. Earlier in the week, Faraday Future Intelligent announced that it will hold a launch event for its China-U.S. Automotive Bridge Strategy on September 19. The electric vehicle maker said the event will provide more details and an execution plan for the strategy and introduction of Faraday's second auto